Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

4(66.7%)

Phase 1

2(33.3%)

6Total

Phase 2(4)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT00015223Phase 2Completed

Methylphenidate in the Treatment of Cocaine Dependent Patients With Adult Attention Deficit Hyperactivity Disorder - 5

Role: collaborator

NCT00015054Phase 2Completed

Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3

Role: collaborator

NCT00015080Phase 2Completed

Naltrexone in Treatment of Cocaine Dependence - 5

Role: collaborator

NCT00015028Phase 2Completed

Buprenorphine/Naloxone for Opiate-Dependence Treatment - 1

Role: collaborator

NCT00015067Phase 1Completed

Cocaine-Methylphendidate Interaction Study - 4

Role: collaborator

NCT00015041Phase 1Completed

Buprenorphine Dose Escalation Trial for Treatment of Non-Dependent Opiate Users - 2

Role: collaborator

All 6 trials loaded